Literature DB >> 12744894

The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children.

Bracha Rager-Zisman1, Elina Bazarsky, Agneta Skibin, Shlomo Chamney, Ilana Belmaker, Iris Shai, Ella Kordysh, Diane E Griffin.   

Abstract

Current policies for measles control call for administration of a second dose of vaccine to immunize those who failed to respond to the initial dose and to boost the responses of those with low levels of antibody. However, there has been concern expressed publicly that reimmunization may have adverse immunologic consequences. To determine the effects of reimmunization on immune responses, primary school children (N=38, mean age=6.14+/-0.35 years) with documented previous measles-mumps-rubella vaccine (MMR) immunization during infancy 4-5 years earlier were studied before and 1 month after receiving MMR as a part of routine reimmunization in Beer-Sheva, Israel. A substantial number of children were seronegative to measles (24%), mumps (34%) and rubella (44%). On reimmunization all seroconverted to mumps and rubella and all but one (92%) seroconverted to measles. The geometric mean titer of measles virus neutralizing antibody increased from 171 to 724 and the greatest increases occurred in those with the lowest pre-immunization titers. Moderate increases in levels of total IgM, IgG and IgE were detected in those with increases in antibody to measles virus. After reimmunization leukocyte counts decreased significantly from (5.8 x 10(6))+/-2.3 to (3.4 x 10(6))+/-0.7 ml(-1) (P=0.0001). The percentages of both CD4(+) and CD8(+) T cells decreased while the CD4:CD8 ratio remained unchanged. The percentage of CD56(+) natural killer (NK) cells increased from 5.2+/-2.7 to 7.2+/-2.8 (P=0.01). Functional assays showed improved lymphoproliferation in response to stimulation with phytohemagglutinin and tetanus toxoid and stable NK lytic activity. Therefore, reimmunization was accompanied by decreased leukocyte counts, but leukocyte function was unchanged or improved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744894     DOI: 10.1016/s0264-410x(03)00053-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.

Authors:  Dhohyung Kim; Devra Huey; Michael Oglesbee; Stefan Niewiesk
Journal:  Blood       Date:  2011-02-28       Impact factor: 22.113

Review 2.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

3.  Measles Virus Enters Breast and Colon Cancer Cell Lines through a PVRL4-Mediated Macropinocytosis Pathway.

Authors:  Sebastien Delpeut; Gary Sisson; Karen M Black; Christopher D Richardson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Guy Tam; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

5.  Care of Children with DiGeorge Before and After Cultured Thymus Tissue Implantation.

Authors:  Stephanie E Gupton; Elizabeth A McCarthy; M Louise Markert
Journal:  J Clin Immunol       Date:  2021-05-18       Impact factor: 8.542

6.  Immune response to second dose of MMR vaccine in Indian children.

Authors:  Sunil Gomber; Shilpa Khanna Arora; Shukla Das; V G Ramachandran
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

7.  Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Authors:  Hoyin Mok; Xing Cheng; Qi Xu; James R Zengel; Bandita Parhy; Jackie Zhao; C Kathy Wang; Hong Jin
Journal:  Open Virol J       Date:  2012-02-16

Review 8.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

9.  Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Authors:  Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

Review 10.  The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbilliviruses.

Authors:  Sebastien Delpeut; Ryan S Noyce; Christopher D Richardson
Journal:  Viruses       Date:  2014-06-02       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.